Exposure‐response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components

摘要

Tocilizumab has a direct effect on inflammatory markers. Therefore, composite measures for disease activity assessment in rheumatoid arthritis (RA) using these inflammatory markers may not be suitable for tocilizumab treatment. We used a modelling approach to describe the tocilizumab exposure‐response relationship and to investigate the different dynamics of the individual components of the routinely used continuous composite measures.